Search Results Search Sort by RelevanceMost Recent Art of Medicine May 2019 Fading Mind of a Patient With Alzheimer’s Laci Hadorn This artwork represents—via a puzzle—physical and emotional experiences of brain deterioration. AMA J Ethics. 2019;21(5):E455-456. doi: 10.1001/amajethics.2019.455. Medicine and Society May 2019 How Should Mechanical Circulatory Support Be Deactivated for Patients With Depression at the End of Life? Stephan R. Weinland, PhD, MS and James Levenson, MD End-stage heart failure patients can experience depression along with their chronic illness. Multidisciplinary responses are critical. AMA J Ethics. 2019;21(5):E429-434. doi: 10.1001/amajethics.2019.429. Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Health Law Jul 2019 Regional Unrepresented Patient Advocacy Committee as an Alternative for Decision Making Lisa K. Anderson-Shaw, DrPH, MA, MSN, ANP-BC A UPAC is an alternative to engaging a guardianship court appointment process or to using physicians or ethics committees as decision makers. AMA J Ethics. 2019;21(7):E594-599. doi: 10.1001/amajethics.2019.594. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Medicine and Society Jul 2019 Who Are “Unrepresented” Patients and What Count as “Important” Medical Decisions for Them? David Ozar, PhD A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs. AMA J Ethics. 2019;21(7):E611-616. doi: 10.1001/amajethics.2019.611. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Art of Medicine May 2019 Fading Mind of a Patient With Alzheimer’s Laci Hadorn This artwork represents—via a puzzle—physical and emotional experiences of brain deterioration. AMA J Ethics. 2019;21(5):E455-456. doi: 10.1001/amajethics.2019.455.
Medicine and Society May 2019 How Should Mechanical Circulatory Support Be Deactivated for Patients With Depression at the End of Life? Stephan R. Weinland, PhD, MS and James Levenson, MD End-stage heart failure patients can experience depression along with their chronic illness. Multidisciplinary responses are critical. AMA J Ethics. 2019;21(5):E429-434. doi: 10.1001/amajethics.2019.429.
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
Health Law Jul 2019 Regional Unrepresented Patient Advocacy Committee as an Alternative for Decision Making Lisa K. Anderson-Shaw, DrPH, MA, MSN, ANP-BC A UPAC is an alternative to engaging a guardianship court appointment process or to using physicians or ethics committees as decision makers. AMA J Ethics. 2019;21(7):E594-599. doi: 10.1001/amajethics.2019.594.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.
Medicine and Society Jul 2019 Who Are “Unrepresented” Patients and What Count as “Important” Medical Decisions for Them? David Ozar, PhD A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs. AMA J Ethics. 2019;21(7):E611-616. doi: 10.1001/amajethics.2019.611.